Business Profile & Competitive Position
Humana Inc. operates in the Healthcare sector, specifically the Medical - Healthcare Plans industry, from its headquarters in Louisville, Kentucky. The company runs two reportable segments: Insurance and CenterWell. The Insurance segment covers Medicare plans, state-based Medicaid, individual and employer plans, specialty benefits, military services, and a pharmacy benefit manager. CenterWell delivers pharmacy solutions, primary care, and home solutions. As of December 31, 2025, Humana served approximately 15.0 million members in medical benefit plans and 4.7 million members in specialty products.
The financial footprint suggests a business with scale but thin profitability. A net margin of 0.9% and ROE of 6.9% indicate that the company converts revenue into shareholder returns only modestly. In healthcare plans, margins are typically compressed by regulatory pricing, medical cost inflation, and reimbursement benchmarks, so these figures are consistent with an industry where competitive advantage comes from membership density, network contracts, and operational efficiency rather than wide pricing power. The federal government is the dominant customer: 83% of 2025 total premiums and services revenue came from federal contracts, including 14% from individual Medicare Advantage contracts in Florida alone, covering roughly 1.0 million members. That concentration creates a moat around government relationships and geographic share, but it also means pricing power is largely determined by CMS rate-setting rather than brand premium.
Financial Posture
Humana currently carries a market capitalization of $49.3 billion and trades at a P/E ratio of 38.5. At first glance, that multiple looks elevated relative to the company's net margin of 0.9% and ROE of 6.9%. A P/E above the mid-thirties for a sub-1% margin business implies the market is pricing in a recovery in earnings power, or is valuing the company on membership, revenue stability, and Medicare Advantage growth rather than current bottom-line profitability.
The stock's beta of 0.74 suggests it has moved less dramatically than the overall market, which is typical for large-cap managed care names tied to recurring premium revenue and government reimbursement schedules. As of the latest snapshot, HUM closed at $410.41 with an RSI of 49.8, essentially neutral momentum, and the price sits above its 50-day EMA of $402.98. The combination of a high P/E, low net margin, and moderate beta points to a stock where valuation is sensitive to forward guidance and any change in Medicare Advantage margin expectations, rather than a deep-value or high-growth profile.
Strategic Priorities & Outlook
Humana's most recent 10-K filing outlines an integrated care delivery model that combines quality care, high member engagement, and sophisticated data analytics as its core strategic framework. The company is prioritizing the simplification of the consumer experience, deeper engagement of members in clinical programs, and assisting providers in moving from fee-for-service to value-based payment arrangements.
Operationally, the filing highlights a meaningful push into value-based care. Approximately 2,260,900 members, or 15.1% of total medical membership, were covered under shared-risk value-based arrangements as of December 31, 2025. Among individual Medicare Advantage members, that share rises to 37.1%. CenterWell's physical presence has also expanded: 350 primary care clinics, roughly 1,300 primary care providers, and approximately 491,100 patients served. Because 83% of premiums and services revenue comes from federal contracts, the success of these priorities will likely be measured by how well they improve benefit cost ratios and Star ratings within Medicare Advantage, which ultimately affect reimbursement rates and retention.
Macro & Geopolitical Exposure
As a Medical - Healthcare Plans company, Humana is inherently exposed to U.S. healthcare regulation and federal fiscal policy. The dominant exposure is to Medicare Advantage reimbursement rates set by the Centers for Medicare & Medicaid Services, along with Medicaid funding levels determined at both federal and state levels. Changes to CMS rate announcements, risk-adjustment methodologies, or Star ratings can move revenue and earnings materially.
Beyond reimbursement, the sector faces exposure to medical cost trends, prescription drug pricing legislation, and broader debates over entitlement spending. Trade policy and currency have limited direct relevance, since the business is almost entirely U.S.-based and service-oriented. Supply chain risk is also relatively low compared to manufacturers, though pharmacy costs and provider network capacity can act as operational constraints. Healthcare reform discussions, court rulings on the Affordable Care Act, and election-cycle policy shifts all represent recurring macro headwinds or tailwinds for the industry.
Recent Developments
The most recent headlines cluster around the upcoming quarterly report. On November 2, 2026, Zacks published a piece titled "Why Humana (HUM) Could Beat Earnings Estimates Again," while just two days earlier, on October 30, 2026, the same outlet ran "Analysts Estimate Humana (HUM) to Report a Decline in Earnings: What to Look Out for." This tension—analysts expecting lower earnings while the historical pattern suggests a possible beat—captures the central debate heading into the next print.
On October 29, 2026, Humana's board declared its regular quarterly dividend, a routine but closely watched signal of cash-flow confidence. Earlier, on October 26, 2026, Seeking Alpha reported that Baron Health Care Fund opened or closed positions in the stock during the third quarter of 2026, a reminder that institutional ownership and fund flows can influence price action independent of earnings results. HUM is scheduled to report next on November 6, 2026, before the market open, with a consensus EPS estimate of $-1.00.
Earnings Behavior & Post-Earnings Drift
Humana's recent earnings record is unusually consistent on the headline number. Over the last eight reported quarters, the company has beaten estimates every time, for a 100% beat rate and an average earnings surprise of 7.9%. That track record would normally set up an expectation that the stock rises after reports, but the price action tells a different story.
The average 5-day price move following earnings across those eight quarters is just 0.06%, classified as flat. In other words, the market has historically priced in the good news quickly, or the beats have been offset by guidance, segment margin commentary, or broader Medicare Advantage concerns. The last four quarters illustrate this disconnect clearly. For the July 29, 2026 report, Humana beat by 4.7% with EPS of $7.61 versus a $7.27 estimate, yet the stock rose only 0.34% the next day and slipped 0.44% over the following five days. On April 29, 2026, a narrow 0.7% beat of $10.31 against $10.24 triggered a 2.75% single-day drop, though the five-day drift recovered to +1.32%.
Even larger beats have failed to hold. The November 5, 2025 quarter saw EPS of $3.24 against a $2.93 estimate, a 10.6% surprise, but the stock fell 5.22% the next day and 9.23% over the following five days. Only the February 11, 2026 quarter behaved like a textbook beat: EPS of $-3.96 versus an estimated $-4.00 (a 1.0% positive surprise) produced a 1.96% next-day gain and an 8.61% five-day rally. That exception aside, the pattern is clear: even on beat quarters, the post-earnings drift has not reliably continued in the direction of the surprise. For traders, the takeaway is that the unofficial consensus and the reaction to guidance matter at least as much as whether Humana clears the consensus EPS number.
Frequently Asked Questions
Why does Humana have a high P/E with such a low net margin?
The P/E of 38.5 reflects the market's expectation that Humana's earnings power can recover from currently depressed margins. The net margin of 0.9% is low by historical standards for large managed care companies, and investors may be pricing in a normalization of Medicare Advantage margins, membership growth, or cost improvements from the CenterWell integration.
How reliant is Humana on government-funded healthcare programs?
According to its 10-K filing, 83% of Humana's 2025 premiums and services revenue came from federal government contracts. A single state concentration is also notable: 14% of total premiums and services revenue came from individual Medicare Advantage contracts in Florida, covering approximately 1.0 million members.
Does Humana stock usually go up after it beats earnings?
Not reliably. Over the last eight quarters, Humana has beaten estimates 100% of the time with an average surprise of 7.9%, yet the average 5-day post-earnings move is just 0.06%, classified as flat. Several recent beats, including a 10.6% surprise in November 2025, were followed by negative price drift, showing that guidance and sector sentiment often outweigh the headline beat.
| Reported | Actual | Estimate | Surprise | 1D Move | 5D Move |
|---|---|---|---|---|---|
| 2026-07-29 | $7.61 | $7.27 | +4.7% | +0.34% | -0.44% |
| 2026-04-29 | $10.31 | $10.24 | +0.7% | -2.75% | +1.32% |
| 2026-02-11 | $-3.96 | $-4 | +1% | +1.96% | +8.61% |
| 2025-11-05 | $3.24 | $2.93 | +10.6% | -5.22% | -9.23% |
| 2025-07-30 | $6.27 | $5.92 | +5.9% | - | - |
| 2025-04-30 | $11.58 | $10.07 | +15% | - | - |
Previous HUM editions
Get the institutional verdict on HUM
Seven-seat 21-ERT council. Pre-print forecast signed before the earnings release. Post-print grade, published in public. Every verdict sealed with a cryptographic receipt.
Read the HUM verdict at Gamma QCVerify authenticity
Every Gamma QC verdict is signed with a cryptographic receipt at issuance. Independently verify any published verdict at attest.gammaqc.com. This educational primer is content-only and not itself signed; the institutional verdict at the link above is.